DOCSLIB.ORG

Mouse Szt2 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Szt2 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Szt2 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Szt2 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Szt2 gene (NCBI Reference Sequence: NM_198170 ; Ensembl: ENSMUSG00000033253 ) is located on Mouse chromosome 4. 72 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 72 (Transcript: ENSMUST00000075406). Exon 42 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Szt2 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-391J10 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for mutations in this gene display increased susceptibility to induced seizures. Mice homozygous for null mutations also display partial penetrance of prenatal lethality. Exon 42 starts from about 57.34% of the coding region. The knockout of Exon 42 will result in frameshift of the gene. The size of intron 41 for 5'-loxP site insertion: 1057 bp, and the size of intron 42 for 3'-loxP site insertion: 1766 bp. The size of effective cKO region: ~630 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 41 42 43 44 45 72 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Szt2 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7130bp) | A(22.86% 1630) | C(24.52% 1748) | T(25.69% 1832) | G(26.93% 1920) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr4 - 118380547 118383546 3000 browser details YourSeq 103 1156 1263 3000 98.2% chr1 + 125172961 125173070 110 browser details YourSeq 75 1131 1257 3000 87.4% chr7 - 79760319 79760433 115 browser details YourSeq 75 1158 1481 3000 71.9% chr1 + 79780570 79780806 237 browser details YourSeq 71 1325 1458 3000 89.9% chr11 - 76091960 76092094 135 browser details YourSeq 70 1311 1465 3000 90.6% chr7 - 84071314 84071480 167 browser details YourSeq 70 1378 1470 3000 82.8% chr3 - 15201237 15201323 87 browser details YourSeq 70 1379 1480 3000 82.2% chr1 + 71888973 71889071 99 browser details YourSeq 64 1379 1466 3000 86.4% chr14 - 25897869 25897956 88 browser details YourSeq 64 1379 1466 3000 86.4% chr14 - 26177253 26177340 88 browser details YourSeq 63 1379 1464 3000 87.3% chr14 - 26037492 26037726 235 browser details YourSeq 62 1323 1466 3000 93.1% chr4 - 142643200 142643343 144 browser details YourSeq 62 1379 1466 3000 88.8% chr16 + 56161841 56161937 97 browser details YourSeq 61 1379 1466 3000 85.1% chr11 - 109314021 109314108 88 browser details YourSeq 60 1400 1478 3000 89.7% chr3 + 108583031 108583452 422 browser details YourSeq 59 1166 1435 3000 90.5% chr3 - 86176458 86176982 525 browser details YourSeq 59 1370 1451 3000 82.5% chr2 - 125586166 125586245 80 browser details YourSeq 58 1376 1451 3000 88.2% chr7 - 118838843 118838918 76 browser details YourSeq 57 1379 1479 3000 78.3% chr6 - 30201041 30201141 101 browser details YourSeq 57 1379 1458 3000 80.6% chr11 - 83390312 83390388 77 Note: The 3000 bp section upstream of Exon 42 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr4 - 118376917 118379916 3000 browser details YourSeq 172 1102 1297 3000 96.3% chr5 - 134609142 134609352 211 browser details YourSeq 163 1109 1293 3000 95.6% chr12 + 111661504 111661689 186 browser details YourSeq 162 1113 1297 3000 96.0% chr1 + 51504536 51504720 185 browser details YourSeq 160 1118 1284 3000 98.3% chr17 - 88020761 88020928 168 browser details YourSeq 160 1118 1281 3000 98.8% chr14 - 61613858 61614021 164 browser details YourSeq 160 1118 1285 3000 97.7% chr12 - 19048819 19048986 168 browser details YourSeq 160 1118 1281 3000 98.8% chr7 + 27399861 27400024 164 browser details YourSeq 160 1118 1281 3000 98.8% chr2 + 20817050 20817213 164 browser details YourSeq 160 1118 1281 3000 98.8% chr15 + 97149450 97149613 164 browser details YourSeq 159 1116 1280 3000 98.2% chr13 - 44708884 44709048 165 browser details YourSeq 159 1113 1281 3000 95.9% chr2 + 119968851 119969018 168 browser details YourSeq 159 1113 1281 3000 97.1% chr2 + 31070375 31070543 169 browser details YourSeq 158 1119 1280 3000 98.8% chr1 - 6091894 6092055 162 browser details YourSeq 158 1118 1281 3000 98.2% chrX + 36815736 36815899 164 browser details YourSeq 157 1118 1280 3000 98.2% chr11 - 78175664 78175826 163 browser details YourSeq 157 1118 1280 3000 98.2% chr18 + 36393775 36393937 163 browser details YourSeq 157 1118 1280 3000 98.2% chr14 + 22232970 22233132 163 browser details YourSeq 157 1118 1280 3000 98.2% chr14 + 8108564 8108726 163 browser details YourSeq 157 1118 1280 3000 98.2% chr12 + 44271610 44271772 163 Note: The 3000 bp section downstream of Exon 42 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Szt2 SZT2 subunit of KICSTOR complex [ Mus musculus (house mouse) ] Gene ID: 230676, updated on 12-Aug-2019 Gene summary Official Symbol Szt2 provided by MGI Official Full Name SZT2 subunit of KICSTOR complex provided by MGI Primary source MGI:MGI:3033336 See related Ensembl:ENSMUSG00000033253 Gene type protein coding RefSeq status REVIEWED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as TIGR; 6430407N22 Summary This gene encodes a protein associated with low seizure threshold in mice and may contribute to susceptibility to epilepsy. Expression [provided by RefSeq, Aug 2011] Orthologs Ubiquitous expression in thymus adult (RPKM 18.9), lung adult (RPKM 13.3) and 28 other tissuesS ee more human all Genomic context Location: 4; 4 D2.1 See Szt2 in Genome Data Viewer Exon count: 72 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 4 NC_000070.6 (118362740..118409286, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 4 NC_000070.5 (118035350..118081868, complement) Chromosome 4 - NC_000070.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 6 transcripts Gene: Szt2 ENSMUSG00000033253 Description SZT2 subunit of KICSTOR complex [Source:MGI Symbol;Acc:MGI:3033336] Gene Synonyms seaizure threshold 2 Location Chromosome 4: 118,362,743-118,409,273 reverse strand. GRCm38:CM000997.2 About this gene This gene has 6 transcripts (splice variants), 227 orthologues, is a member of 1 Ensembl protein family and is associated with 9 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Szt2- ENSMUST00000075406.11 10965 3431aa ENSMUSP00000074862.5 Protein coding CCDS51283 A2A9C3 TSL:1 201 GENCODE basic APPRIS P1 Szt2- ENSMUST00000183402.7 3652 559aa ENSMUSP00000139348.1 Nonsense mediated - V9GXW1 CDS 5' 206 decay incomplete TSL:1 Szt2- ENSMUST00000138386.1 791 No - Retained intron - - TSL:3 204 protein Szt2- ENSMUST00000138632.1 605 No - Retained intron - - TSL:3 205 protein Szt2- ENSMUST00000130058.1 599 No - lncRNA - - TSL:2 202 protein Szt2- ENSMUST00000136737.1 444 No - lncRNA - - TSL:5 203 protein Page 6 of 8 https://www.alphaknockout.com 66.53 kb Forward strand 118.36Mb 118.37Mb 118.38Mb 118.39Mb 118.40Mb 118.41Mb Genes Hyi-205 >polymorphic pseudogene Med8-204 >protein coding (Comprehensive set... Hyi-202 >nonsense mediated decay Med8-203 >protein coding Hyi-204 >retained intron Med8-206 >protein coding Hyi-201 >protein coding Med8-202 >protein coding Hyi-203 >retained intron Med8-207 >lncRNA Med8-201 >protein coding Med8-209 >protein coding Med8-210 >lncRNA Med8-205 >lncRNA Med8-208 >lncRNA Contigs AL627212.21 > Genes (Comprehensive set... < Szt2-201protein coding < Szt2-206nonsense mediated decay < Szt2-203lncRNA < Szt2-202lncRNA < Szt2-204retained intron < Szt2-205retained intron Regulatory Build 118.36Mb 118.37Mb 118.38Mb 118.39Mb 118.40Mb 118.41Mb Reverse strand 66.53 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding pseudogene RNA gene processed transcript Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000075406 < Szt2-201protein coding Reverse strand 46.53 kb ENSMUSP00000074... MobiDB lite Low complexity (Seg) PANTHER Protein SZT2 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend frameshift variant missense variant splice region variant synonymous variant Scale bar 0 400 800 1200 1600 2000 2400 2800 3431 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC.
Load more

Recommended publications
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Plasma Proteomic Analysis Reveals Altered Protein Abundances In
    Lygirou et al. J Transl Med (2018) 16:104 https://doi.org/10.1186/s12967-018-1476-9 Journal of Translational Medicine RESEARCH Open Access Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease Vasiliki Lygirou1 , Agnieszka Latosinska2, Manousos Makridakis1, William Mullen3, Christian Delles3, Joost P. Schanstra4,5, Jerome Zoidakis1, Burkert Pieske6, Harald Mischak2 and Antonia Vlahou1* Abstract Background: Cardiovascular disease (CVD) describes the pathological conditions of the heart and blood vessels. Despite the large number of studies on CVD and its etiology, its key modulators remain largely unknown. To this end, we performed a comprehensive proteomic analysis of blood plasma, with the scope to identify disease-associated changes after placing them in the context of existing knowledge, and generate a well characterized dataset for fur- ther use in CVD multi-omics integrative analysis. Methods: LC–MS/MS was employed to analyze plasma from 32 subjects (19 cases of various CVD phenotypes and 13 controls) in two steps: discovery (13 cases and 8 controls) and test (6 cases and 5 controls) set analysis. Follow- ing label-free quantifcation, the detected proteins were correlated to existing plasma proteomics datasets (plasma proteome database; PPD) and functionally annotated (Cytoscape, Ingenuity Pathway Analysis). Diferential expression was defned based on identifcation confdence ( 2 peptides per protein), statistical signifcance (Mann–Whitney p value 0.05) and a minimum of twofold change.≥ ≤ Results: Peptides detected in at least 50% of samples per group were considered, resulting in a total of 3796 identi- fed proteins (838 proteins based on 2 peptides). Pathway annotation confrmed the functional relevance of the fndings (representation of complement≥ cascade, fbrin clot formation, platelet degranulation, etc.).
    [Show full text]
  • An Amino Acid Deletion Inszt2 in a Family with Non- Syndromic Intellectual Disability
    An Amino Acid Deletion inSZT2 in a Family with Non- Syndromic Intellectual Disability Michelle Falcone1, Kemal O. Yariz1, David B. Ross2, Joseph Foster II1, Ibis Menendez1, Mustafa Tekin1* 1 Dr. John T. Macdonald Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, United States of America, 2 Comprehensive Neurobehavioral Institute, Plantation, Florida, United States of America Abstract Autosomal recessive intellectual disability (ID) is characterized by extensive genetic heterogeneity. Recently, three mutations in SZT2 were reported in two unrelated children with unexplained infantile epileptic encephalopathy with severe ID. Here we report a European American family with three children having non-syndromic mild or moderate ID without seizures. Whole-exome sequencing of three affected siblings revealed a three base pair deletion (c. 4202_4204delTTC) located in a 19 mb autozygous region on chromosome 1, leading to an amino acid deletion (p.Phe1401del) in SZT2. All three children were homozygous for the deletion and their parents were heterozygous as expected in autosomal recessive inheritance. SZT2 is highly expressed in neuronal tissues and regulates seizure threshold and neuronal excitation in mice. We conclude that the disruption of SZT2 with some residual function might lead to mild or moderate ID without seizures. Citation: Falcone M, Yariz KO, Ross DB, Foster J, Menendez I, et al. (2013) An Amino Acid Deletion inSZT2 in a Family with Non-Syndromic Intellectual Disability. PLoS ONE 8(12): e82810. doi:10.1371/journal.pone.0082810 Editor: Andreas R. Janecke, Innsbruck Medical University, Austria Received September 13, 2013; Accepted November 7, 2013; Published December 6, 2013 Copyright: © 2013 Falcone et al.
    [Show full text]
  • Developmental and Epileptic Encephalopathy Due to SZT2 Genomic Variants: Emerging Features of a Syndromic Condition
    Epilepsy & Behavior 108 (2020) 107097 Contents lists available at ScienceDirect Epilepsy & Behavior journal homepage: www.elsevier.com/locate/yebeh Review Developmental and epileptic encephalopathy due to SZT2 genomic variants: Emerging features of a syndromic condition Marina Trivisano a, Manuel Rivera a,b, Alessandra Terracciano c,AndreaCiolfi d, Antonio Napolitano e, Chiara Pepi f, Costanza Calabrese a, Maria Cristina Digilio g, Marco Tartaglia d, Paolo Curatolo f, Federico Vigevano h,i, Nicola Specchio a,i,⁎ a Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy b Departamento de Neuropediatria, Fleni, Montañeses 2325, C1428AQK Ciudad de Buenos Aires, Argentina c Laboratory of Medical Genetics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy d Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy e Neuroradiology Unit, Department of Imaging, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy f Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, Via Montpellier 1, 00133 Rome, Italy g Medical Genetics, Department of Pediatrics, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy h Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome i Member of European Reference Network EpiCARE article info abstract Article history: Seizure threshold 2 (SZT2) gene mutations have been associated with developmental and epileptic encephalop- Received 1 April 2020 athies (DEEs). Following a literature review, we collected 22 patients and identified the main clinical features re- Revised 4 April 2020 lated to SZT2 variants that are epilepsy with onset within the first years of life, intellectual disability (ID), Accepted 4 April 2020 macrocephaly with dysmorphic facial features, corpus callosum (CC) shape abnormalities, and cortical migration Available online 11 May 2020 disorders.
    [Show full text]
  • Rabbit Anti-C1orf84 /FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-C1orf84 /FITC Conjugated antibody SL15077R-FITC Product Name: Anti-C1orf84 /FITC Chinese Name: FITC标记的1号染色体开放阅读框84抗体 Chromosome 1 open reading frame 84; Hypothetical protein LOC149469; Alias: Uncharacterized protein C1orf84; SZT2_HUMAN. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Cow,Horse,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 378kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human C1orf84 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Storewww.sunlongbiotech.com at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: SZT2 (seizure threshold 2 homolog (mouse)), also known as SZT2A or SZT2B, is a 3,432 amino acid peroxisomal protein that plays a role in resistance to oxidative stress. Predominantly expressed in the parietal and frontal cortex, as well as in dorsal root Product Detail: ganglia of the brain, SZT2 is implicated in superoxide dismutase activity and the neuroprotection in peroxisomes.
    [Show full text]
  • A Molecular Quantitative Trait Locus Map for Osteoarthritis
    ARTICLE https://doi.org/10.1038/s41467-021-21593-7 OPEN A molecular quantitative trait locus map for osteoarthritis Julia Steinberg 1,2,3,4, Lorraine Southam1,3, Theodoros I. Roumeliotis3,5, Matthew J. Clark 6, Raveen L. Jayasuriya6, Diane Swift6, Karan M. Shah 6, Natalie C. Butterfield 7, Roger A. Brooks8, Andrew W. McCaskie8, J. H. Duncan Bassett 7, Graham R. Williams 7, Jyoti S. Choudhary 3,5, ✉ ✉ J. Mark Wilkinson 6,9,11 & Eleftheria Zeggini 1,3,10,11 1234567890():,; Osteoarthritis causes pain and functional disability for over 500 million people worldwide. To develop disease-stratifying tools and modifying therapies, we need a better understanding of the molecular basis of the disease in relevant tissue and cell types. Here, we study primary cartilage and synovium from 115 patients with osteoarthritis to construct a deep molecular signature map of the disease. By integrating genetics with transcriptomics and proteomics, we discover molecular trait loci in each tissue type and omics level, identify likely effector genes for osteoarthritis-associated genetic signals and highlight high-value targets for drug development and repurposing. These findings provide insights into disease aetiopathology, and offer translational opportunities in response to the global clinical challenge of osteoarthritis. 1 Institute of Translational Genomics, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany. 2 Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia. 3 Wellcome Sanger Institute, Hinxton, United Kingdom. 4 School of Public Health, The University of Sydney, Sydney, NSW, Australia. 5 The Institute of Cancer Research, London, United Kingdom. 6 Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.
    [Show full text]
  • Investigating Developmental and Epileptic Encephalopathy Using Drosophila Melanogaster
    International Journal of Molecular Sciences Review Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster Akari Takai 1 , Masamitsu Yamaguchi 2,3, Hideki Yoshida 2 and Tomohiro Chiyonobu 1,* 1 Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; [email protected] 2 Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto 603-8585, Japan; [email protected] (M.Y.); [email protected] (H.Y.) 3 Kansai Gakken Laboratory, Kankyo Eisei Yakuhin Co. Ltd., Kyoto 619-0237, Japan * Correspondence: [email protected] Received: 15 August 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: Developmental and epileptic encephalopathies (DEEs) are the spectrum of severe epilepsies characterized by early-onset, refractory seizures occurring in the context of developmental regression or plateauing. Early infantile epileptic encephalopathy (EIEE) is one of the earliest forms of DEE, manifesting as frequent epileptic spasms and characteristic electroencephalogram findings in early infancy. In recent years, next-generation sequencing approaches have identified a number of monogenic determinants underlying DEE. In the case of EIEE, 85 genes have been registered in Online Mendelian Inheritance in Man as causative genes. Model organisms are indispensable tools for understanding the in vivo roles of the newly identified causative genes. In this review, we first present an overview of epilepsy and its genetic etiology, especially focusing on EIEE and then briefly summarize epilepsy research using animal and patient-derived induced pluripotent stem cell (iPSC) models. The Drosophila model, which is characterized by easy gene manipulation, a short generation time, low cost and fewer ethical restrictions when designing experiments, is optimal for understanding the genetics of DEE.
    [Show full text]
  • Signatures of Adaptive Evolution in Platyrrhine Primate Genomes 5 6 Hazel Byrne*, Timothy H
    1 2 Supplementary Materials for 3 4 Signatures of adaptive evolution in platyrrhine primate genomes 5 6 Hazel Byrne*, Timothy H. Webster, Sarah F. Brosnan, Patrícia Izar, Jessica W. Lynch 7 *Corresponding author. Email [email protected] 8 9 10 This PDF file includes: 11 Section 1: Extended methods & results: Robust capuchin reference genome 12 Section 2: Extended methods & results: Signatures of selection in platyrrhine genomes 13 Section 3: Extended results: Robust capuchins (Sapajus; H1) positive selection results 14 Section 4: Extended results: Gracile capuchins (Cebus; H2) positive selection results 15 Section 5: Extended results: Ancestral Cebinae (H3) positive selection results 16 Section 6: Extended results: Across-capuchins (H3a) positive selection results 17 Section 7: Extended results: Ancestral Cebidae (H4) positive selection results 18 Section 8: Extended results: Squirrel monkeys (Saimiri; H5) positive selection results 19 Figs. S1 to S3 20 Tables S1–S3, S5–S7, S10, and S23 21 References (94 to 172) 22 23 Other Supplementary Materials for this manuscript include the following: 24 Tables S4, S8, S9, S11–S22, and S24–S44 1 25 1) Extended methods & results: Robust capuchin reference genome 26 1.1 Genome assembly: versions and accessions 27 The version of the genome assembly used in this study, Sape_Mango_1.0, was uploaded to a 28 Zenodo repository (see data availability). An assembly (Sape_Mango_1.1) with minor 29 modifications including the removal of two short scaffolds and the addition of the mitochondrial 30 genome assembly was uploaded to NCBI under the accession JAGHVQ. The BioProject and 31 BioSample NCBI accessions for this project and sample (Mango) are PRJNA717806 and 32 SAMN18511585.
    [Show full text]
  • Analysis of RHOA Mutations and Their Significance in the Proliferation and Transcriptome of Digestive Tract Cancer Cells
    ONCOLOGY LETTERS 22: 735, 2021 Analysis of RHOA mutations and their significance in the proliferation and transcriptome of digestive tract cancer cells NAOKI IKARI1,2, AKIKO SERIZAWA1, ETSUKO TANJI2, MASAKAZU YAMAMOTO1 and TORU FURUKAWA1‑3 1Department of Surgery, Institute of Gastroenterology; 2Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Shinjuku‑ku, Tokyo 162‑8666; 3Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai 980‑8575, Japan Received April 23, 2021; Accepted July 14, 2021 DOI: 10.3892/ol.2021.12996 Abstract. The ras homolog family member A (RHOA) gene showed that the genes associated with small molecule metabolic encodes a member of the Rho family of small GTPases and is process, oxidation‑reduction processes, protein kinase activity, known to function in reorganization of the actin cytoskeleton, transport, and cell junction were commonly downregulated in which is associated with regulation of cell shape, attachment cells whose proliferation was attenuated by the knockdown of and motility. RHOA has been found to be recurrently mutated RHOA. These results suggested that certain RHOA mutations in gastrointestinal cancer; however, the functional signifi‑ may result in upregulation of lnc‑DERA‑1 and genes associated cance of the mutated RHOA protein in digestive tract cancers with cellular metabolism and proliferation in digestive tract remains to be uncovered. The aim of the present study was cancers. to understand the role of mutant RHOA in the proliferation and transcriptome of digestive tract cancer cells. Mutations of Introduction RHOA in one esophageal cancer cell line, OE19, eight gastric cancer cell lines, namely, AGS, GCIY, HGC‑27, KATO III, The ras homolog family member A (RHOA) gene encodes a MKN1, MKN45, SNU16 and SNU719, as well as two colon member of the Rho family of small GTPases and is known cancer cell lines, CCK‑81 and SW948, were determined using to function in reorganization of the actin cytoskeleton, which Sanger sequencing.
    [Show full text]
  • Constitutive Activation of Mtorc1 Signaling Induced by Biallelic Loss-Of-Function Mutations in SZT2 Underlies a Discernible Neurodevelopmental Disease
    RESEARCH ARTICLE Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in SZT2 underlies a discernible neurodevelopmental disease 1 1,2 3 3 Yuji NakamuraID , Kohji Kato , Naomi Tsuchida , Naomichi Matsumoto , Yoshiyuki Takahashi2, Shinji Saitoh1* a1111111111 1 Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 2 Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, a1111111111 Japan, 3 Department of Human Genetics, Yokohama City University Graduate School of Medicine, a1111111111 Yokohama, Japan a1111111111 a1111111111 * [email protected] Abstract OPEN ACCESS There have been increasing number of reports of SZT2-related neurological diseases, the Citation: Nakamura Y, Kato K, Tsuchida N, main symptoms of which are epilepsy, developmental delay, macrocephaly and a dysmor- Matsumoto N, Takahashi Y, Saitoh S (2019) phic corpus callosum. SZT2 functions as a regulator of mechanistic target of rapamycin Constitutive activation of mTORC1 signaling induced by biallelic loss-of-function mutations in complex 1 (mTORC1) signaling in cultured human cell lines and mouse tissues. However, it SZT2 underlies a discernible neurodevelopmental remains to be determined whether mutations in SZT2 in human patients alter mTORC1 sig- disease. PLoS ONE 14(8): e0221482. https://doi. naling. In this study, we aimed to investigate the functional consequence of biallelic SZT2 org/10.1371/journal.pone.0221482 variants in Epstein-Barr virus-induced lymphoblastoid cell lines (LCLs) established from two Editor: Andreas R. Janecke, Medizinische patients with a typical SZT2-related neurodevelopmental disease. Increased phosphoryla- Universitat Innsbruck Department fur Kinder- und tion of S6 kinase and S6 was identified in patient-derived cell lines under amino acid-starved Jugendheilkunde, AUSTRIA condition, suggestive of constitutive hyperactivation of mTORC1 signaling.
    [Show full text]
  • Genetic Characteristics of Non-Familial Epilepsy
    Genetic characteristics of non-familial epilepsy Kyung Wook Kang1, Wonkuk Kim2, Yong Won Cho3, Sang Kun Lee4, Ki-Young Jung4, Wonchul Shin5, Dong Wook Kim6, Won-Joo Kim7, Hyang Woon Lee8, Woojun Kim9, Keuntae Kim3, So-Hyun Lee10, Seok-Yong Choi10 and Myeong-Kyu Kim1 1 Department of Neurology, Chonnam National University Medical School, Gwangju, South Korea 2 Department of Applied Statistics, Chung-Ang University, Seoul, South Korea 3 Department of Neurology, Keimyung University Dongsan Medical Center, Daegu, South Korea 4 Department of Neurology, Seoul National University Hospital, Seoul, South Korea 5 Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, South Korea 6 Department of Neurology, Konkuk University School of Medicine, Seoul, South Korea 7 Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 8 Department of Neurology, Ewha Womans University School of Medicine and Ewha Medical Research Institute, Seoul, South Korea 9 Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea 10 Department of Biomedical Science, Chonnam National University Medical School, Gwangju, South Korea ABSTRACT Background: Knowledge of the genetic etiology of epilepsy can provide essential prognostic information and influence decisions regarding treatment and management, leading us into the era of precision medicine. However, the genetic basis underlying epileptogenesis or epilepsy pharmacoresistance is not well-understood, particularly in non-familial epilepsies with heterogeneous phenotypes that last until or start in adulthood. Methods: We sought to determine the contribution of known epilepsy-associated Submitted 25 June 2019 genes (EAGs) to the causation of non-familial epilepsies with heterogeneous Accepted 22 November 2019 phenotypes and to the genetic basis underlying epilepsy pharmacoresistance.
    [Show full text]
  • Next-Generation Sequencing Technologies and Neurogenetic Diseases
    life Review Next-Generation Sequencing Technologies and Neurogenetic Diseases Hui Sun † , Xiao-Rong Shen †, Zi-Bing Fang, Zong-Zhi Jiang, Xiao-Jing Wei, Zi-Yi Wang and Xue-Fan Yu * Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun 130021, China; [email protected] (H.S.); [email protected] (X.-R.S.); [email protected] (Z.-B.F.); [email protected] (Z.-Z.J.); [email protected] (X.-J.W.); [email protected] (Z.-Y.W.) * Correspondence: [email protected]; Tel.: +86-157-5430-1836 † These authors made equal contributions to this study. Abstract: Next-generation sequencing (NGS) technology has led to great advances in understanding the causes of Mendelian and complex neurological diseases. Owing to the complexity of genetic diseases, the genetic factors contributing to many rare and common neurological diseases remain poorly understood. Selecting the correct genetic test based on cost-effectiveness, coverage area, and sequencing range can improve diagnosis, treatments, and prevention. Whole-exome sequencing and whole-genome sequencing are suitable methods for finding new mutations, and gene panels are suitable for exploring the roles of specific genes in neurogenetic diseases. Here, we provide an overview of the classifications, applications, advantages, and limitations of NGS in research on neurological diseases. We further provide examples of NGS-based explorations and insights of the genetic causes of neurogenetic diseases, including Charcot–Marie–Tooth disease, spinocerebellar ataxias, epilepsy, and multiple sclerosis. In addition, we focus on issues related to NGS-based Citation: Sun, H.; Shen, X.-R.; Fang, analyses, including interpretations of variants of uncertain significance, de novo mutations, congenital Z.-B.; Jiang, Z.-Z.; Wei, X.-J.; Wang, genetic diseases with complex phenotypes, and single-molecule real-time approaches.
    [Show full text]